

Appendix 1. Data on cardiovascular drugs aimed at treating the underlying structural cardiac disease administered to 55 dogs with atrial fibrillation at the time of study inclusion.

ACVIM Stage	B2		C		D	
Cardiac disease (No. of dogs)	MMVD (3)	DCM (2)	MMVD (34)	DCM (13)	MMVD (3)	DCM (0)
Cardiac drug (No. of dogs) [median dose at study inclusion]	None	None	Furosemide (22) [4 mg/kg/day]	Furosemide (2) [2.4 mg/kg/day]	Furosemide (3) [7.6 mg/kg/day]	-
			Pimobendan (18) [0.52 mg/kg/day]	Pimobendan (1) [0.2 mg/kg/day]	Pimobendan (18) [0.7 mg/kg/day]	
			Benazepril (13) [0.6 mg/kg/day]		Benazepril (13) [0.64 mg/kg/day]	
			Spiroinolactone (5) [1.8 mg/kg/day]		Enalapril (1) [1.2 mg/kg/day]	
			Enalapril (2) [0.55 mg/kg/day]		Spiroinolactone (1) [1.3 mg/kg/day]	
			Amlodipine (1) [0.18 mg/kg/day]		Torasemide (1) [0.2 mg/kg/day]	
			Hydrochlorothiazide (1) [0.7 mg/kg q48h]			

ACVIM: American College of Veterinary Internal Medicine; B2: dogs from MMVD group with cardiac enlargement or dogs from DCM group showing left ventricular systolic dysfunction with or without concurrent left ventricular chamber enlargement in diastole; C: dogs with MMVD or DCM and past or present clinical signs of congestive heart failure; D: dogs with MMVD or DCM and clinical signs of congestive heart failure refractory to standard treatment; DCM: dilated cardiomyopathy; MMVD: myxomatous mitral valve disease;